Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-na&#239;ve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.

Tagrisso (osimertinib) - AstraZeneca

Semena (befotertinib) - InventisBio, Betta Pharma

Ivesa (firmonertinib) - Allist, ArriVent

Vizimpro (dacomitinib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42734867

Hansraj Kumar; Harminder Singh; Jameema Thankachan; Seshadri Reddy Varikasuvu; Shiv Mudgal; Subodh Kumar; Sumit Mahato

Sep 15, 2026